1.Factors affecting the Fatigue of Hospitalized Women Cancer Patients Receiving Chemotherapy.
Kyunghee KIM ; Myosuk LEE ; Yeunhee KWAK ; Ji Su KIM
Asian Oncology Nursing 2014;14(3):182-190
PURPOSE: The purpose of this study was to identify factors that influence fatigue in hospitalized women cancer patients receiving chemotherapy. METHODS: The participants were 117 women cancer patients receiving chemotherapy. The instruments used in this study were physical symptoms, mood state, family support, and fatigue scales for patients with cancer. Data were analyzed using descriptive statistics, t-test, ANOVA, Pearson correlation coefficients and multiple regression with the IBM SPSS 19.0 program. RESULTS: Fatigue showed significant correlation with physical symptoms such as side effects as well as sub-elements of mood status such as anxiety-depression, vitality, anger and family support. Fatigue-anticipating variables were found to be some sub-elements of mood state such as anxiety-depression (beta=.61, t=10.40, p<.001), digestion organ factor (beta=.78, t=2.54, p=.013) and pain/fatigue factor (beta=.86, t=0.43, p=.045). The total variance explained was 69.7%. CONCLUSION: These results showed that the factors affecting fatigue were physical symptoms, and the mood state of hospitalized women cancer patients receiving chemotherapy. The results of this study provided basic materials for a nursing intervention program to reduce fatigue.
Anger
;
Digestion
;
Drug Therapy*
;
Fatigue*
;
Female
;
Humans
;
Nursing
;
Weights and Measures
3.Nausea/Vomiting and Anxiety of Hospitalized Cancer Patients Receiving Chemotherapy.
Ja Yun CHOI ; Hyang Sook SO ; In Sook CHO
Journal of Korean Academy of Adult Nursing 2004;16(2):211-221
PURPOSE: The purpose of this study was to describe the pattern of changes on the score of nausea/vomiting and anxiety during one cycle of chemotherapy. METHOD: A total of 53 subjects who were admitted to C University Hospital for a period of 3 days and 2 nights for chemotherapy were selected from February to April, 2003. Total scores of nausea/vomiting were measured twice a day 3 days for a total of 6 measurements. Anxiety, anorexia, and fatigue were also measured at the first and last measurement points. Data were analyzed by one-way repeated measures, ANOVA, t-test, paired t-test, & Pearson's correlation. RESULT: The score of nausea/vomiting increased over time except for the 4th measurement point but no changes were significant over time. There were the significant differences between 1st and 2nd, and 2nd and 3rd nausea/vomiting score at p < 0.05. The scores of anxiety, anorexia, and fatigue between the first and 6th points were significantly different(t=-5.69, p=.001; t=6.25, p=.0001; t=3.65, p=.0007). CONCLUSION: Further studies are needed to identify the relationship between anxiety, and anticipatory and acute nausea/vomiting respectively.
Anorexia
;
Anxiety*
;
Drug Therapy*
;
Fatigue
;
Humans
;
Nausea
;
Vomiting
5.Traditional Chinese medical comprehensive therapy for cancer-related fatigue.
Lu YANG ; Tian-Tian LI ; Yu-Ting CHU ; Ke CHEN ; Shao-Dan TIAN ; Xin-Yi CHEN ; Guo-Wang YANG
Chinese journal of integrative medicine 2016;22(1):67-72
Cancer-related fatigue (CRF) is a common and one of the most severe symptom in the period of onset, diagnosis, treatment and rehabilitation process of cancer. But there are no confirmed measures to relieve this problem at present. Traditional Chinese medical comprehensive therapy has its advantages in dealing with this condition. Based on the research status of CRF, the following problems have been analyzed and solved: the term of CRF has been defined and recommended, and the definition has been made clear; the disease mechanism is proposed, i.e. healthy qi has been impaired in the long-term disease duration, in the process of surgery, chemotherapy, radiotherapy and biology disturbing; it is clear that the clinical manifestations are related to six Chinese medicine patterns: decreased functioning of the Pi (Spleen) and Wei (Stomach), deficiency of the Pi with dampness retention, deficiency of the Xin (Heart) and Pi, disharmony between the Gan (Liver) and Pi, deficiency of the Pi and Shen (Kidney), and deficiency of the Fei (Lung) and Shen. Based on its severity, the mild patients are advised to have non-drug psychological intervention and sleep treatment in cooperation with appropriate exercise; diet therapy are recommended to moderate patients together with sleep treatment and acupuncture, severe patients are recommended to have herbal treatment based on pattern differentiation together with physiological sleep therapy.
Fatigue
;
drug therapy
;
etiology
;
Humans
;
Medicine, Chinese Traditional
;
Neoplasms
;
complications
;
drug therapy
6.Efficacy and Safety of Lianhua Qingwen for Patients with COVID-19: A Systematic Review and Meta-Analysis.
Xiao-Hu SUN ; Shuo ZHANG ; Zhen YANG ; Zhen-Lin CHEN ; Shi-Jun YUE ; Sai ZHANG ; Yu-Ping TANG
Chinese journal of integrative medicine 2022;28(7):650-660
BACKGROUND:
Corona virus disease 2019 (COVID-19) has spread around the world since its outbreak, and there is no ascertained effective drug up to now. Lianhua Qingwen (LHQW) has been widely used in China and overseas Chinese, which had some advantages in the treatment of COVID-19.
OBJECTIVE:
To evaluate the efficacy and safety of LHQW for COVID-19 by conducting a systematic review with meta-analysis.
METHODS:
A comprehensive literature search was conducted in 12 electronic databases from their establishment to October 30, 2021. Note Express 3.2.0 was used for screening of trials, and the data was independently extracted in duplicate by 2 researchers. The risk of bias of randomized controlled trials (RCTs) and retrospective studies were assessed by using the Cochrane collaboration tool and Newcastle Ottawa Scale, respectively, followed by data analysis using RevMan 5.3. The RCTs or retrospective studies to treat COVID-19 using LHQW were included. The intervention measures in the experimental group were LHQW alone or combined with chemical drugs (LCWC), and that in the control group were chemical drugs (CDs). Outcome measures included computed tomography (CT) recovery rate, disappearance rates of primary (fever, cough, fatigue), respiratory, gastrointestinal and other symptoms, exacerbation rate and adverse reaction. Subgroup analysis was conducted according to whether LHQW was combined with CDs and the different treatment methods in the control group.
RESULTS:
Nine trials with 1,152 participants with COVID-19 were included. The CT recovery rates of LHQW and LCWC were 1.36 and 1.32 times of CDs, respectively (P<0.05). Compared with CDs, LCWC remarkably increased the disappearance rates of fever, cough, fatigue, expectoration, shortness of breath, and muscle soreness (P<0.05). LHQW also obviously decreased the exacerbation rate, which was 0.45 times of CDs alone (P<0.05). There was no obvious difference between LCWC and CDs in adverse reaction (P>0.05).
CONCLUSIONS
LHQW was more suitable for treating COVID-19 patients with obvious expectoration, shortness of breath and muscle soreness. LHQW had advantages in treating COVID-19 with no obvious exacerbation. (PROSPERO No. CRD42021235937).
COVID-19/drug therapy*
;
Cough/drug therapy*
;
Drugs, Chinese Herbal/adverse effects*
;
Dyspnea/drug therapy*
;
Fatigue/drug therapy*
;
Humans
;
Myalgia/drug therapy*
7.Chemical constituents contained in ethanol extracts from Acorus tatarinowii and their anti-fatigue activity.
Mei-ju ZHU ; Ning-hua TAN ; Jing-yu XIONG ; Chang-jiu JI ; Hong-zhu ZHU ; Jun-ju XU ; Qi-jun LUO
China Journal of Chinese Materia Medica 2012;37(19):2898-2901
Chemical constituents in ethyl acetate and butanol fractions of ethanol extracts from Acorus tatarinowii were separated by column chromatography. Bufo skeletal muscle fatigue model was established to study the anti-fatigue activity of separated compounds. Five compounds were separated and identified by spectroscopic analysis as acoramone(1),cycloartenone(2),2,4,5-trimethoxyl-2'-butoxy-1,2-phenyl propandiol(3),5-hydroxymethyl furfural(4), and 5-butoxymethyl furfural(5). Compound 3 was a new compound, and compounds 2 and 5 were separated from this plant for the first time. Compound 4 exhibited a notable anti-fatigue activity.
Acorus
;
chemistry
;
Animals
;
Bufonidae
;
Fatigue
;
drug therapy
;
Muscle, Skeletal
;
drug effects
;
Plant Extracts
;
chemistry
;
pharmacology
8.Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study
Joon Young HUR ; Youjin KIM ; Ghee Young KWON ; Minyong KANG ; Hyun Hwan SUNG ; Hwang Gyun JEON ; Byong Chang JEONG ; Seong Il SEO ; Seong Soo JEON ; Hyun Moo LEE ; Su Jin LEE ; Se Hoon PARK
Cancer Research and Treatment 2019;51(4):1269-1274
PURPOSE: Treatment targeting immune checkpoint with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has demonstrated efficacy and tolerability in the treatment of metastatic urothelial carcinoma (mUC). We investigated the efficacy and safety of atezolizumab in mUC patients who failed platinum-based chemotherapy. MATERIALS AND METHODS: A retrospective study using the Samsung Medical Center cancer chemotherapy registry was performed on 50 consecutive patients with mUC treated with atezolizumab, regardless of their PD-L1(SP142) status, as salvage therapy after chemotherapy failure between May 2017 and June 2018. Endpoints included overall response rate (RR), progression-free survival (PFS), and safety. RESULTS: Among 50 patients, men constituted 76% and the median age was 68 years (range, 46 to 82 years). Twenty-three patients (46%) received atezolizumab as second-line therapy. PD-L1 (SP142) status IC0/1 and IC2/3 were found in 21 (42%) and 21 (42%) of patients, respectively; in eight patients (16%), PD-L1 (SP142) expression was not available. Atezolizumab was generally well tolerated, with pruritus and fatigue being the most commonly observed toxicities. As a result, partial response was noted in 20 patients (40%), with 12 (24%) stable diseases. RRwas higherin IC2/3 (62%) than in IC0/1 patients (24%, p=0.013). The median PFS was 7.4 months (95% confidence interval, 3.4 to 11.4 months). As expected, PFS also was significantly longer in IC2/3 patients than in IC0/1 (median, 12.7 vs. 2.1 months; p=0.005). PFS was not significantly influenced by age, sex, performance status, number of previous chemotherapy, site of metastases, or any of the baseline laboratory parameters. CONCLUSION: In this retrospective study, atezolizumab demonstrated clinically efficacy and tolerability in unselected mUC patients who failed platinum-based chemotherapy.
Disease-Free Survival
;
Drug Therapy
;
Fatigue
;
Humans
;
Male
;
Neoplasm Metastasis
;
Pruritus
;
Retrospective Studies
;
Salvage Therapy
9.Effects of a Laughter Therapy on Depression, Anxiety, Fatigue and Quality of Sleep in Gastrointestinal Cancer Patients Post-Treatment: a Randomized Controlled Trial
SeYeon PARK ; YimSun LEE ; Hyun Hoon CHUNG ; Smi CHOI-KWON
Journal of Korean Biological Nursing Science 2019;21(3):188-198
PURPOSE: The purpose of this study was to examine the effect of laughter therapy on depression, anxiety, fatigue, and quality of sleep in gastrointestinal cancer survivors. METHODS: This study was a randomized controlled trial. We compared the effect of laughter therapy with usual care only in post chemotherapy gastrointestinal patients. Outcomes included changes in depression and anxiety (according to the Hospital Anxiety and Depression Scale), fatigue (according to the Fatigue Severity Scale), and quality of sleep (according to the Verran & Synder-Halpern Sleep Scale). Data was collected July 2015 through January 2016. Seventy nine participants who agreed to participate in this study were randomized to either the experimental group (n=40) or the control group (n=39). Therapy included eight sessions (60 minutes each, once weekly). Data were analyzed using the Windows SPSS 22.0 program. RESULTS: Laughter therapy was effective in reducing fatigue (p=.019) and increasing satisfaction of sleep (p=.030). There were no differences between the groups after therapy for depression (p=.129) and anxiety (p=.200). CONCLUSION: Results of this study indicate that laughter therapy may be an effective nursing intervention for improving the health status of gastrointestinal cancer survivors after chemotherapy.
Anxiety
;
Depression
;
Drug Therapy
;
Fatigue
;
Gastrointestinal Neoplasms
;
Humans
;
Laughter Therapy
;
Laughter
;
Nursing
;
Survivors
10.The Trajectory of Fatigue and Quality of Life in Stomach Cancer Patients Receiving Chemotherapy.
Journal of Korean Academy of Nursing 2002;32(4):482-491
PURPOSE: This study aimed to identify the change patterns of fatigue and quality of life during consecutive chemotherapies and to determine the relationship of these two variables. METHOD: Stomach cancer patients receiving chemotherapy were recruited from a university hospital in Seoul. Each chemotherapy, subjects were asked to respond to the questionnaires regarding their fatigue and quality of life. The number of subjects who completed 4 cycles and over was 11. Fatigue was measured with Lee's tool(1999). Quality of life was measured with a tool revised by the author based on Padilla et al(1983). RESULT: Most patients were in 1st stage(5 patients) or 3rd stage(5 patients). Fatigue was revealed at its highest level in the 3rd or 4th chemotherapy and at its lowest level in the 1st or 6th chemotherapy. A quality of life appeared at its highest level in the 5th or 6th chemotherapy and the lowest level in 3rd or 4th chemotherapy. CONCLUSION: Among 6 cycles of chemotherapy, in 3-4th chemotherapy the fatigue was the highest and the quality of life were the lowest. Many patients decided to stop treatment at the same period. Therefore we can recognize cancer patients receiving chemo- therapy are in the highest risk at the time of the 3-4 th chemotherapy.
Drug Therapy*
;
Fatigue*
;
Humans
;
Quality of Life*
;
Surveys and Questionnaires
;
Seoul
;
Stomach Neoplasms*
;
Stomach*